Clinical Trials
89 trialsNCT01774630 2026-05-26
NiloPost-STIM
University Hospital, Bordeaux
Phase 2 Completed
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT02379416 2026-04-21
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT03874858 2026-04-02
DANTE
Novartis
Phase 2 Completed
NCT01207492 2026-02-20
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00756509 2026-01-20
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Novartis
Phase 4 Completed
NCT01407198 2025-12-19
Nilotinib With Radiation for High Risk Chordoma
Massachusetts General Hospital
Phase 1 Completed
NCT01316250 2025-10-02
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
American University of Beirut Medical Center
Phase NA Completed
NCT02201459 2025-10-02
PETALs
Hospices Civils de Lyon
Phase 3 Completed
NCT01784068 2025-09-10
ENESTfreedom
Novartis
Phase 2 Completed
NCT01698905 2025-09-02
ENESTop
Novartis
Phase 2 Completed
NCT07138378 2025-08-22
XS003-11
Xspray Pharma AB
Phase 1 Completed
NCT04205903 2025-06-29
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT01860456 2025-06-05
TIKlet
University of Pisa
Completed
NCT01804985 2025-03-14
DESTINY
University of Liverpool
Phase 2 Completed
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT01863745 2024-08-19
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Phase 2 Completed
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT02081378 2024-03-18
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
Novartis
Phase 1 Completed
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT05286528 2023-10-27
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
Completed
NCT05734053 2023-08-21
NOFRETETE
Novartis
Completed
NCT01657604 2023-05-10
TIGER
University of Jena
Phase 3 Completed
NCT02269267 2023-03-03
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Medical College of Wisconsin
Phase 2 Completed
NCT03885830 2023-01-11
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
UNC Lineberger Comprehensive Cancer Center
Completed
NCT02546674 2022-07-22
NILOdeepR
Novartis
Phase 4 Completed
NCT02353728 2022-03-25
Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy
Weill Medical College of Cornell University
Phase 2 Completed
NCT00481052 2022-01-18
CML0307
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT00769327 2022-01-04
CML0408
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01743989 2021-07-15
ENESTPath
Novartis
Phase 3 Completed
NCT00980018 2021-07-01
MACS0999
Novartis
Phase 4 Completed
NCT00109707 2021-06-29
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Novartis
Phase 1/2 Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT01856283 2021-01-13
Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
Niguarda Hospital
Phase 2 Completed
NCT01702064 2021-01-05
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01077544 2020-12-29
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 1 Completed
NCT01223898 2020-12-09
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
Novartis
Phase 1 Completed
NCT01456676 2020-12-09
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
Novartis
Phase 1 Completed
NCT00135005 2020-12-08
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 1 Completed
NCT00384228 2020-12-08
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
Novartis
Phase 1/2 Completed
NCT01279473 2020-12-08
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
Novartis
Phase 1/2 Completed
NCT00471497 2020-11-18
ENESTnd
Novartis
Phase 3 Completed
NCT01914484 2020-11-02
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
Phase 1/2 Completed
NCT01274351 2020-09-01
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT01528085 2020-07-30
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Goethe University
Phase 2 Completed
NCT01140568 2020-05-05
Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
University of California, San Diego
Phase 2 Completed
NCT01155817 2020-04-15
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
Stanford University
Phase 1 Completed
NCT01744665 2020-03-10
ENESTgoal
Novartis
Phase 2 Completed